Navigation Links
Roche Starts Early Stage Clinical Trial in Down Syndrome

BASEL, Switzerland and NUTLEY, N.J., Sept. 9, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of its first Phase 1 clinical trial to investigate the safety and tolerability of a molecule designed to address the cognitive and behavioral deficits associated with Down syndrome.

"There is currently a large unmet medical need for the treatment of cognitive impairments in individuals suffering from Down syndrome," comments Luca Santarelli, Global Head of Roche Neurosciences Disease Translational Area. "Our strategy at Roche neurosciences is to specifically address these serious conditions that have no approved, effective or safe treatment. This is why we have a strong commitment to neurodevelopmental disorders, including genetic disorders like Down syndrome or Fragile X, as well as autism spectrum disorders."  

Enhancing brain functions such as cognition and language in individuals with Down syndrome holds the promise to help these individuals conduct a more independent life. This may result from the improved ability to carry out every day's practical tasks such as finding an apartment, maintaining a job, or having a more fulfilling social life. These improvements can have a significant impact on functioning and quality of life of Down syndrome individuals as well as help reduce the burden for families, caregivers and the society.

"This study will target only adults between 18 and 30 years old, but we believe that an earlier intervention in Down syndrome has the potential for a greater medical impact," says Paulo Fontoura, Head of Translational Medicine in the Roche Neurosciences Disease Translational Area. "While we are still at the early stage, we are confident that our drug's mechanism of action can potentially open the door to further promising investigations in upcoming years."

Based on animal models, an imbalance between excitatory and inhibitory neurotransmission has been proposed among the underlying causes of altered brain function in individuals with Down syndrome. Roche's investigational drug is being assessed for its ability to address this imbalance by targeting the GABAergic* system.

*GABA: gamma-amino butyric acid

About the study

This placebo-controlled study will assess the safety and tolerability of the investigational drug in individuals with Down syndrome. It will recruit up to 33 individuals in one or two countries. For more information on the study, access the Roche Clinical Trials Protocol Registry and Results Database:

About Down syndrome

Down syndrome is the most common genetic cause of intellectual disability and developmental delay, and affects one in every 700-1000 newborns. Also called Trisomy 21, this condition occurs when an individual has three, rather than two, copies of the 21st chromosome. This additional genetic material causes some impairment of cognitive ability and physical growth, and is often associated with other complications ranging from neurological and cardiac defects to hearing and vision problems. It is now thought that many people with Down syndrome are more likely to develop Alzheimer's disease as they age.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4
2. Rochester Medical Reports Fiscal 2011 Third Quarter Results
3. Rochester Medical Announces Third Quarter 2011 Earnings Conference Call Thursday, July 28, 2011
4. Roche NimbleGen and Caliper Collaborate to Offer Automated Target Enrichment Pipeline Solution for Next-Generation Sequencing
5. In Support of the International Day of the African Child, Roche Hosts Annual Childrens Walk
6. Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date
7. Roche and Clovis Oncology to Co-Develop EGFR Companion Diagnostic
8. Florida Hospital First U.S. Site to Adopt New Automated Laboratory Solution From Roche
9. Roche Symposium Showcases Accomplishments of Next Generation of Chemists
10. Roche Submits Application for Clearance of Chlamydia and Gonorrhoeae Test
11. Rochester Medical Reports Second Quarter Results
Post Your Comments:
(Date:12/1/2015)... , BANGALORE, India and ... -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it ... approval and for developing country markets funded by international ... 300 mg + Efavirenz 400 mg) for $99 per ... Access Initiative (CHAI) to develop TLE400. The significantly reduced ...
(Date:12/1/2015)... diciembre de 2015  AccuTEC Blades, una ... precisión, develó hoy un nuevo logo corporativo ... El nuevo logo destaca la experiencia de ... de productos con cuchillas donde "el borde ... --> ...
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... as a Modern Man for 2015. , Angeleno Magazine is a division ... States. Established in 1994, Modern Luxury includes more than 50 magazine titles across ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... Beard and Brooke Bennett are collaborating with brands across various categories through traditional ... influential figures make up an elite group of Gold Medal Moms who can ...
(Date:11/30/2015)... & Caicos Islands, BWI (PRWEB) , ... December 01, 2015 , ... ... 2015. Recently Caribbean Journal, one of the leading digital news sites highlighting Caribbean ... top reason? The weather. While much of North America shivers under chilly grey ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, 2015 , ... ... as a 2015-2016 inductee into its VIP Woman of the Year Circle. She ... is the nation’s leading networking organization exclusively for professional women, boasting more than 850,000 ...
Breaking Medicine News(10 mins):